Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors

被引:28
作者
Dicker, Ira B. [1 ]
Terry, Brian [1 ]
Lin, Zeyu [1 ]
Li, Zhufang [1 ]
Bollini, Sagarika [1 ]
Samanta, Himadri K. [1 ]
Gali, Volodymyr [1 ]
Walker, Michael A. [2 ]
Krystal, Mark R. [1 ]
机构
[1] Bristol Myers Squibb Res & Dev, Dept Virol, Wallingford, CT 06492 USA
[2] Bristol Myers Squibb Res & Dev, Dept Med Chem, Wallingford, CT 06492 USA
关键词
D O I
10.1074/jbc.M804213200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this study, eight different HIV-1 integrase proteins containing mutations observed in strand transfer inhibitor- resistant viruses were expressed, purified, and used for detailed enzymatic analyses. All the variants examined were impaired for strand transfer activity compared with the wild type enzyme, with relative catalytic efficiencies ( kp/ Km) ranging from 0.6 to 50% of wild type. The origin of the reduced strand transfer efficiencies of the variant enzymes was predominantly because of poorer catalytic turnover ( kp) values. However, smaller secondorder effects were caused by up to 4- fold increases in Km values for target DNA utilization in some of the variants. All the variants were less efficient than the wild type enzyme in assembling on the viral long terminal repeat, as each variant required more protein than wild type to attain maximal activity. In addition, the variant integrases displayed up to 8- fold reductions in their catalytic efficiencies for 3'-processing. The Q148R variant was the most defective enzyme. The molecular basis for resistance of these enzymes was shown to be due to lower affinity binding of the strand transfer inhibitor to the integrase complex, a consequence of faster dissociation rates. In the case of the Q148R variant, the origin of reduced compound affinity lies in alterations to the active site that reduce the binding of a catalytically essential magnesium ion. Finally, except for T66I, variant viruses harboring the the resistance-inducing substitutions were defective for viral integration.
引用
收藏
页码:23599 / 23609
页数:11
相关论文
共 51 条
[31]   Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors [J].
Lee, DJ ;
Robinson, WE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) :134-142
[32]   Human immunodeficiency virus type 1 (HIV-1) integrase: Resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid [J].
Lee, DJ ;
Robinson, WE .
JOURNAL OF VIROLOGY, 2004, 78 (11) :5835-5847
[33]   Retroviral DNA integration: reaction pathway and critical intermediates [J].
Li, M ;
Mizuuchi, M ;
Burke, TR ;
Craigie, R .
EMBO JOURNAL, 2006, 25 (06) :1295-1304
[34]  
MCCOLL DJ, 2007, 16 INT HIV RES WORKS
[35]  
Miller MD, 2008, 17 INT HIV DRUG RES
[36]   Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga [J].
Neamati, N .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (05) :709-724
[37]   Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding [J].
O'Doherty, U ;
Swiggard, WJ ;
Malim, MH .
JOURNAL OF VIROLOGY, 2000, 74 (21) :10074-10080
[38]   A sensitive, quantitative assay for human immunodeficiency virus type 1 integration [J].
O'Doherty, U ;
Swiggard, WJ ;
Jeyakumar, D ;
McGain, D ;
Malim, MH .
JOURNAL OF VIROLOGY, 2002, 76 (21) :10942-10950
[39]   Integrase inhibitors to treat HIV/AIDS [J].
Pommier, Y ;
Johnson, AA ;
Marchand, C .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (03) :236-248
[40]  
REN C, 2007, 16 INT HIV RES WORKS